Local Application of Mineral-Coated Microparticles Loaded With VEGF and BMP-2 Induces the Healing of Murine Atrophic Non-Unions
Overview
Authors
Affiliations
Deficient angiogenesis and disturbed osteogenesis are key factors for the development of nonunions. Mineral-coated microparticles (MCM) represent a sophisticated carrier system for the delivery of vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP)-2. In this study, we investigated whether a combination of VEGF- and BMP-2-loaded MCM (MCM + VB) with a ratio of 1:2 improves bone repair in non-unions. For this purpose, we applied MCM + VB or unloaded MCM in a murine non-union model and studied the process of bone healing by means of radiological, biomechanical, histomorphometric, immunohistochemical and Western blot techniques after 14 and 70 days. MCM-free non-unions served as controls. Bone defects treated with MCM + VB exhibited osseous bridging, an improved biomechanical stiffness, an increased bone volume within the callus including ongoing mineralization, increased vascularization, and a histologically larger total periosteal callus area consisting predominantly of osseous tissue when compared to defects of the other groups. Western blot analyses on day 14 revealed a higher expression of osteoprotegerin (OPG) and vice versa reduced expression of receptor activator of NF-κB ligand (RANKL) in bone defects treated with MCM + VB. On day 70, these defects exhibited an increased expression of erythropoietin (EPO), EPO-receptor and BMP-4. These findings indicate that the use of MCM for spatiotemporal controlled delivery of VEGF and BMP-2 shows great potential to improve bone healing in atrophic non-unions by promoting angiogenesis and osteogenesis as well as reducing early osteoclast activity.
Guo C, Ding T, Cheng Y, Zheng J, Fang X, Feng Z Front Bioeng Biotechnol. 2025; 13:1548675.
PMID: 40078794 PMC: 11897010. DOI: 10.3389/fbioe.2025.1548675.
Methods to accelerate fracture healing - a narrative review from a clinical perspective.
Ganse B Front Immunol. 2024; 15:1384783.
PMID: 38911851 PMC: 11190092. DOI: 10.3389/fimmu.2024.1384783.
Saul D, Menger M, Ehnert S, Nussler A, Histing T, Laschke M Bioengineering (Basel). 2023; 10(1).
PMID: 36671657 PMC: 9855128. DOI: 10.3390/bioengineering10010085.